Compare Cassava Sciences Inc (FLNA) vs Tilray Brands Inc (TLRY) Price & Performance

FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.

Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.

TLRY trades at $4.36, down 0.57% on the day, amid a bearish technical signal and mixed quarterly earnings. The company reported a net loss of -$2.19 billion for 2025 despite revenue growth to $821 million, with a negative net income margin of -156.67%. Recent developments include medical cannabis expansion in Panama and the acquisition of HelloMD to enhance digital healthcare capabilities.

While low valuation ratios (P/S of 0.55, P/B of 0.35) suggest potential undervaluation, persistent losses and negative cash flow from operations pose significant risks. Analyst sentiment is cautious with a 'Hold' consensus, reflecting concerns over profitability despite growth initiatives. The stock's outlook hinges on achieving sustainable profitability and navigating competitive and regulatory pressures.